331 related articles for article (PubMed ID: 15647651)
1. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Orr WC
Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):113-20. PubMed ID: 15647651
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
4. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
5. The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
Thomson AB
Clin Drug Investig; 2007; 27(10):663-72. PubMed ID: 17803341
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
7. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
9. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
[TBL] [Abstract][Full Text] [Related]
10. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of gastro-oesophageal reflux in children.
Tighe MP; Andrews E; Liddicoat I; Afzal NA; Hayen A; Beattie RM
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD008550. PubMed ID: 37635269
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Kovacs TO; Wilcox CM; DeVault K; Miska D; Bochenek W;
Aliment Pharmacol Ther; 2002 Dec; 16(12):2043-52. PubMed ID: 12452936
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Zheng RN
World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
15. An overview of proton pump inhibitors.
Der G
Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
[TBL] [Abstract][Full Text] [Related]
16. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
Gillessen A; Beil W; Modlin IM; Gatz G; Hole U
J Clin Gastroenterol; 2004 Apr; 38(4):332-40. PubMed ID: 15087692
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
18. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
19. Role of pantoprazole in the treatment of gastro-oesophageal reflux disease.
Lehmann FS; Beglinger C
Expert Opin Pharmacother; 2005 Jan; 6(1):93-104. PubMed ID: 15709887
[TBL] [Abstract][Full Text] [Related]
20. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
Scholten T; Teutsch I; Bohuschke M; Gatz G
Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
